Armata CEO has 4,919 shares withheld for taxes

Armata Pharmaceuticals’ CEO Deborah Birx reported a routine tax-withholding transaction involving company stock.

Rhea-AI Filing Summary

Armata Pharmaceuticals’ CEO Deborah Birx reported a routine tax-withholding transaction involving company stock. On this Form 4, 4,919 shares of common stock were withheld by the company at $10.54 per share to cover income-tax obligations tied to the net settlement of restricted stock units. This was a tax-withholding disposition, not an open-market sale, and left Birx with direct ownership of 212,458 common shares.

Insider Trade Summary

Exercise Price or Tax Liability: 4,919 shares

Exercise Price or Tax Liability 1 txn

Insider Birx Deborah

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	4,919	$10.54	$52K

Holdings After Transaction: Common Stock — 212,458 shares (Direct)

Footnotes (1)

1. F1. Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units.

FAQ

What did Armata Pharmaceuticals (ARMP) CEO Deborah Birx report on this Form 4?

Deborah Birx reported a tax-withholding disposition of common stock. The company withheld shares to satisfy its income tax and withholding obligations related to the net settlement of restricted stock units, rather than Birx selling shares in the open market.

How many Armata Pharmaceuticals (ARMP) shares were withheld for taxes in this filing?

The transaction involved 4,919 shares of Armata Pharmaceuticals common stock. These shares were withheld by the company at $10.54 per share to cover income tax and withholding remittance obligations arising from the net settlement of restricted stock units awarded to Deborah Birx.

Does this Armata Pharmaceuticals (ARMP) Form 4 show an open-market stock sale by the CEO?

No, it does not show an open-market sale. The Form 4 records a tax-withholding disposition, where 4,919 shares were withheld by the company to satisfy tax obligations related to restricted stock units, rather than shares being sold on the open market.

How many Armata Pharmaceuticals (ARMP) shares does Deborah Birx hold after this transaction?

After the tax-withholding transaction, Deborah Birx directly holds 212,458 shares of Armata Pharmaceuticals common stock. This figure reflects her position following the company’s withholding of 4,919 shares to meet income tax and withholding remittance obligations on vested restricted stock units.

What does transaction code "F" mean in this Armata Pharmaceuticals (ARMP) Form 4?

Transaction code “F” indicates a tax-withholding disposition. In this case, 4,919 shares were delivered back to Armata Pharmaceuticals to satisfy income tax and withholding obligations triggered by the net settlement of restricted stock units granted to CEO Deborah Birx.

Is the Armata Pharmaceuticals (ARMP) CEO’s transaction related to restricted stock units (RSUs)?

Yes. The footnote explains the withheld shares relate to the net settlement of restricted stock units. Armata Pharmaceuticals withheld 4,919 shares from CEO Deborah Birx to cover income tax and withholding remittance obligations arising when those RSUs settled into common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 07:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Birx Deborah

(Last) (First) (Middle)

5005 MCCONNELL AVENUE

(Street)

LOS ANGELES CA 90066

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Armata Pharmaceuticals, Inc. [ ARMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/14/2026		F		4,919(1)	D	$10.54	212,458	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units.

	/s/ Deborah Birx	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.